Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly To Partner With Indian Drug Makers In Wake Of Patent Protection (India)

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly is engaging in joint ventures with Indian pharmaceuticals to take advantage of their move to research and development and away from generics. U.S.-based Lilly's CEO said his company is interested in getting involved in global trials with companies that develop their own drugs as far as the Phase III stage. Sidney Taurel also said India's adoption of new patent protections is welcomed by firms such as his. Among companies Taurel mentioned were Jubilant Biosys, Nicholas Piramal India and Suven Pharmaceuticals. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts